Tufts latest to tap TriNetX as the research network aims to expand globally

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CarlosAndreSantos)
(Image: Getty/CarlosAndreSantos)
Tufts Medical Center has joined TriNetX’s research network to improve its clinical trial process, further expanding the company’s reach as it looks to grow internationally and introduce new offerings in 2018.

Biopharmaceutical companies and contract research organization (CROs) using the TriNetX platform will now be able to identify Tufts Medical Center as a viable research partner, according to the company.

“Tufts Medical Center found TriNetX’s query and analytics capabilities provided them with the ability to dig deeper into its clinical data both to recruit eligible patients into clinical trials and to generate new hypotheses for investigation,”​ Gadi Lachman, CEO of TriNetX, told Outsourcing-Pharma.com.

The center joins Boston Children’s Hospital​ as TriNetX’s second healthcare organization member located in downtown Boston. It has 415-beds and brings an additional one million patient lives to TriNetX’s global health research network.

With the onboarding of several new members this year – including Pfizer​ and Sanofi​ – Lachman said: “the network is delivering on the benefit of attracting more clinical trials and fostering collaboration.”

“In 2018, we are going to be introducing new offerings to members that enable their PIs to leverage the network’s data for grant-based research, thus further extending the value proposition for healthcare organizations looking to join TriNetX,”​ he said.

“We are also seeing more international organizations joining,”​ Lachman added.

TriNetX is currently in 11 countries and is targeting to be in 20 by year-end.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars